J
Juan Carlos García-Pagán
Researcher at University of Barcelona
Publications - 379
Citations - 30238
Juan Carlos García-Pagán is an academic researcher from University of Barcelona. The author has contributed to research in topics: Portal hypertension & Portal venous pressure. The author has an hindex of 90, co-authored 348 publications receiving 25573 citations. Previous affiliations of Juan Carlos García-Pagán include University of North Carolina at Charlotte & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Early Use of TIPS in Patients with Cirrhosis and Variceal Bleeding
Juan Carlos García-Pagán,Karel Caca,Christophe Bureau,Wim Laleman,Beate Appenrodt,Angelo Luca,Juan G. Abraldes,Frederik Nevens,Jean-Pierre Vinel,Joachim Mössner,Jaime Bosch +10 more
TL;DR: In patients with cirrhosis who were hospitalized for acute variceal bleeding and at high risk for treatment failure, the early use of TIPS was associated with significant reductions in treatment failure and in mortality.
Journal ArticleDOI
Beta-Blockers to Prevent Gastroesophageal Varices in Patients with Cirrhosis
Roberto J. Groszmann,Guadalupe Garcia-Tsao,Jaime Bosch,Norman D. Grace,Andrew K. Burroughs,Ramon Planas,Angels Escorsell,Juan Carlos García-Pagán,David Patch,Daniel S. Matloff,Hong Gao,Robert W. Makuch +11 more
TL;DR: Nonselective beta-blockers are ineffective in preventing varices in unselected patients with cirrhosis and portal hypertension and are associated with an increased number of adverse events.
Journal ArticleDOI
Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure
Jordi Bruix,Antoni Castells,Jackie Bosch,F Feu,Josep Fuster,Juan Carlos García-Pagán,Josep Visa,Conxita Bru,Joan Rodés +8 more
TL;DR: Cirrhotics with increased portal pressure are at high risk of hepatic decompensation after resection of hepatocellular carcinoma, and surgical resection should therefore be restricted to patients without portal hypertension.
Journal ArticleDOI
The clinical use of HVPG measurements in chronic liver disease
TL;DR: The main clinical applications for HVPG include diagnosis, risk stratification, identification of patients with hepatocellular carcinoma who are candidates for liver resection, monitoring of the efficacy of medical treatment, and assessment of progression of portal hypertension.
Journal ArticleDOI
Hemodynamic response to pharmacological treatment of portal hypertension and long-term prognosis of cirrhosis.
Juan G. Abraldes,Ilaria Tarantino,Juan Turnes,Juan Carlos García-Pagán,Juan Rodés,Jaime Bosch +5 more
TL;DR: In cirrhotic patients receiving pharmacologic treatment for prevention of variceal rebleeding, a decrease in HVPG ≥20% or to ≤12 mm Hg is associated with a marked reduction in the long‐term risk of developing complications of portal hypertension and with improved survival.